Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 81.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 137,838 shares of the company’s stock after buying an additional 61,800 shares during the period. Rockefeller Capital Management L.P. owned 0.14% of Intellia Therapeutics worth $1,607,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of NTLA. Barclays PLC grew its holdings in shares of Intellia Therapeutics by 17.7% during the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock worth $6,017,000 after purchasing an additional 44,022 shares during the last quarter. Geode Capital Management LLC lifted its stake in Intellia Therapeutics by 2.2% in the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock valued at $48,164,000 after buying an additional 49,367 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Intellia Therapeutics in the third quarter valued at approximately $417,000. Sanctuary Advisors LLC increased its holdings in shares of Intellia Therapeutics by 147.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 53,590 shares of the company’s stock valued at $1,101,000 after acquiring an additional 31,976 shares during the period. Finally, Franklin Resources Inc. raised its position in Intellia Therapeutics by 10.3% in the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Trading Up 5.4 %

Shares of NTLA opened at $7.23 on Monday. The company has a 50-day moving average of $8.89 and a two-hundred day moving average of $12.11. The stock has a market cap of $748.43 million, a P/E ratio of -1.33 and a beta of 2.23. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18.

Analysts Set New Price Targets

A number of research firms have commented on NTLA. JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Citigroup increased their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Wells Fargo & Company dropped their target price on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Chardan Capital decreased their price target on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a report on Friday, February 28th. Finally, Wedbush reissued a “neutral” rating and issued a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.